|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 AIM ImmunoTech Inc. 10-Q 9/30/22 75:5M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 980K
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 26K
3: EX-10.4 Material Contract HTML 23K
4: EX-10.5 Material Contract HTML 73K
5: EX-10.6 Material Contract HTML 36K
6: EX-10.7 Material Contract HTML 27K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
16: R1 Cover HTML 73K
17: R2 Consolidated Balance Sheets (Unaudited) HTML 104K
18: R3 Consolidated Balance Sheets (Unaudited) HTML 36K
(Parenthetical)
19: R4 Consolidated Statement of Operations and HTML 92K
Comprehensive Loss (Unaudited)
20: R5 Consolidated Statement of Changes in Stockholders' HTML 69K
Equity (Unaudited)
21: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 117K
22: R7 Business and Basis of Presentation HTML 36K
23: R8 Net Loss Per Share HTML 25K
24: R9 Equity-Based Compensation HTML 101K
25: R10 Marketable Securities HTML 41K
26: R11 Accrued Expenses HTML 29K
27: R12 Property and Equipment, net HTML 32K
28: R13 Patents HTML 34K
29: R14 Stockholders? Equity HTML 66K
30: R15 Cash and Cash Equivalents HTML 24K
31: R16 Recent Accounting Pronouncements HTML 23K
32: R17 Fair Value HTML 96K
33: R18 Financing Obligation Arising from Sale Leaseback HTML 29K
Transaction
34: R19 Leases HTML 52K
35: R20 Research, Consulting and Supply Agreements HTML 31K
36: R21 Subsequent Events HTML 26K
37: R22 Equity-Based Compensation (Tables) HTML 100K
38: R23 Marketable Securities (Tables) HTML 40K
39: R24 Accrued Expenses (Tables) HTML 27K
40: R25 Property and Equipment, net (Tables) HTML 28K
41: R26 Patents (Tables) HTML 35K
42: R27 Fair Value (Tables) HTML 82K
43: R28 Leases (Tables) HTML 28K
44: R29 Business and Basis of Presentation (Details HTML 27K
Narrative)
45: R30 Net Loss Per Share (Details Narrative) HTML 25K
46: R31 Schedule of Stock Option Activity (Details) HTML 83K
47: R32 Schedule of Unvested Stock Option Activity HTML 59K
(Details)
48: R33 Equity-Based Compensation (Details Narrative) HTML 27K
49: R34 Schedule of Available for Sale (Details) HTML 26K
50: R35 Schedule of Equity Securities (Details) HTML 27K
51: R36 Marketable Securities (Details Narrative) HTML 22K
52: R37 Schedule of Accrued Expenses (Details) HTML 31K
53: R38 Schedule of Property and Equipment (Details) HTML 33K
54: R39 Property and Equipment, net (Details Narrative) HTML 30K
55: R40 Schedule of Patents, Trademark Rights (Details) HTML 28K
56: R41 Schedule of Amortization of Patents and Trademarks HTML 36K
(Details)
57: R42 Patents (Details Narrative) HTML 24K
58: R43 Stockholders? Equity (Details Narrative) HTML 167K
59: R44 Schedule of Assumptions to Estimate Fair Value of HTML 49K
Warrants (Details)
60: R45 Schedule of Range of Probabilities (Details) HTML 28K
61: R46 Schedule of Assets and Liabilities Measured at HTML 34K
Fair Value on a Recurring Basis (Details)
62: R47 Schedule of Changes in Level 3 Liabilities HTML 27K
Measured at Fair Value on a Recurring Basis
(Details)
63: R48 Schedule of Assets and Liabilities Measured at HTML 34K
Fair Value on a Nonrecurring Basis (Details)
64: R49 Schedule of Assets and Liabilities Measured at HTML 30K
Fair Value on a NonRecurring Basis (Details)
(Parenthetical)
65: R50 Fair Value (Details Narrative) HTML 28K
66: R51 Financing Obligation Arising from Sale Leaseback HTML 40K
Transaction (Details Narrative)
67: R52 Schedule of Operating lease Future Payments HTML 37K
(Details)
68: R53 Leases (Details Narrative) HTML 73K
69: R54 Research, Consulting and Supply Agreements HTML 41K
(Details Narrative)
70: R55 Subsequent Events (Details Narrative) HTML 25K
73: XML IDEA XML File -- Filing Summary XML 124K
71: XML XBRL Instance -- form10-q_htm XML 1.09M
72: EXCEL IDEA Workbook of Financial Reports XLSX 108K
12: EX-101.CAL XBRL Calculations -- aim-20220930_cal XML 157K
13: EX-101.DEF XBRL Definitions -- aim-20220930_def XML 456K
14: EX-101.LAB XBRL Labels -- aim-20220930_lab XML 898K
15: EX-101.PRE XBRL Presentations -- aim-20220930_pre XML 689K
11: EX-101.SCH XBRL Schema -- aim-20220930 XSD 132K
74: JSON XBRL Instance as JSON Data -- MetaLinks 310± 444K
75: ZIP XBRL Zipped Folder -- 0001493152-22-032118-xbrl Zip 270K
Exhibit 10.7
FOURTH AMENDMENT TO AGREEMENT OF SALE AND PURCHASE
THIS FOURTH AMENDMENT TO AGREEMENT OF SALE AND PURCHASE (this “Fourth Amendment”) is made as of October 21, 2022, by and between AIM IMMUNOTECH INC., a Delaware corporation (“Seller”), ACELLORIES, INC., a New York corporation (“Original Buyer”), and BH 783 JERSEY AVE, LLC, a New Jersey limited liability company (“New Buyer”).
WHEREAS, Seller and Original Buyer have executed that certain Agreement of Sale and Purchase dated March 3, 2022, as amended by a First Amendment to Agreement of Sale and Purchase dated June 27, 2022, a Second Amendment to Agreement of Sale and Purchase dated August 2, 2022 and a Third Amendment to Agreement of Sale and Purchase dated August 31, 2022 (collectively, the “Purchase Agreement”) for the purchase of certain Property, as defined in the Purchase Agreement, situate in the City of Brunswick, Middlesex County, New Jersey and commonly known as 783 Jersey Avenue (“Property”); and
WHEREAS, Seller, Original Buyer and New Buyer now desire to make certain amendments to the Purchase Agreement, upon and subject to the terms and conditions of this Fourth Amendment.
NOW THEREFORE, the parties hereto, in consideration of the mutual promises hereinafter set forth, and intending to be legally bound, hereby agree as follows:
1. New Buyer is hereby substituted for Original Buyer under the Purchase Agreement in all respects, and all references to “Buyer” in the Purchase Agreement shall mean and refer to New Buyer.
2. New Buyer acknowledges and reaffirms that it is purchasing the Property on a strictly “AS IS” basis as set forth in Section 11 of the Purchase Agreement.
3. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement. This Fourth Amendment may be signed in counterpart(s). For purposes of this Fourth Amendment, facsimile or electronic signatures shall constitute original signatures. The transmission of a signed counterpart of this Fourth Amendment by electronic signature, facsimile or by portable document file shall have the same force and effect as delivery of an original signed counterpart of this Fourth Amendment, and shall constitute valid and effective delivery for all purposes. Except as expressly modified hereby, and in all respects, the remainder of the Purchase Agreement is hereby ratified and shall continue in full force and effect without modification.
[Signatures on Following Page]
C:
IN WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to be duly executed as of the day and year first above written.
| Seller: | ||
| AIM IMMUNOTECH INC. | ||
| By: | /s/ Peter W. Rodino | |
| Name: | Peter W. Rodino | |
| Title: | C.O.O. | |
| Original Buyer: | ||
| ACELLORIES, INC. | ||
| By: | /s/ Albert Lalou | |
| Name: | Albert Lalou | |
| Title: | V.P. | |
| New Buyer: | ||
| BH 783 JERSEY AVE, LLC | ||
| By: | /s/ Albert Lalou | |
| Name: | Albert Lalou | |
| Title: | Managing Member | |
C:
| - C: 2- |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | 8-A12B/A | ||
| 10/21/22 | ||||
| For Period end: | 9/30/22 | |||
| 8/31/22 | ||||
| 8/2/22 | ||||
| 6/27/22 | ||||
| 3/3/22 | 4, 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 11/14/23 AIM ImmunoTech Inc. 10-Q 9/30/23 64:5.5M M2 Compliance LLC/FA 8/14/23 AIM ImmunoTech Inc. 10-Q 6/30/23 63:5.3M M2 Compliance LLC/FA 5/15/23 AIM ImmunoTech Inc. 10-Q 3/31/23 65:4.7M M2 Compliance LLC/FA 5/12/23 AIM ImmunoTech Inc. 8-A12B/A 2:384K M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 2/10/23 AIM ImmunoTech Inc. 8-A12B/A 2:60K M2 Compliance LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA |